Request Demo

Last update 03 Apr 2026

Olanzapine

Last update 03 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder.

Drug Type

Small molecule drug

Synonyms

2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Olanzapin, olanzapine LAI

+ [40]

Target

5-HT2A receptor x 5-HT2C receptor x D2 receptor x HTR3

Action

antagonists

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders

Active Indication

Chemotherapy-induced nausea and vomitingAgitationDepressive Disorder+ [8]

Inactive Indication

Anorexia NervosaBorderline Personality DisorderBronchopulmonary Dysplasia+ [7]

Originator Organization

Eli Lilly & Co.

Active Organization

CHEPLAPHARM Arzneimittel GmbHViatris Ltd. (New Zealand)Glenmark Arzneimittel GmbH

+ [7]

Inactive Organization

Qilu Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.PLIVA Croatia Ltd.

+ [7]

License Organization

Teva Pharmaceutical Industries Ltd.

Eli Lilly & Co.

Starton Therapeutics, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

European Union (27 Sep 1996),

Bipolar DisorderManiaSchizophrenia

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC17H20N4S

InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N

CAS Registry132539-06-1

605

Clinical Trials associated with Olanzapine

NCT07442890

/ Not yet recruitingNot ApplicableIIT

A Cohort Study of the Combination Regimen Based on Rolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy in Lung Cancer Patients

This study aims to evaluate the efficacy and safety of a combination regimen based on Rolapitant Palonosetron injection for preventing nausea and vomiting induced by concurrent chemoradiotherapy in lung cancer patients. It will also analyze the differences in preventive efficacy between two combination regimens, filling the gap in antiemetic data for radiotherapy combined with moderately to highly emetogenic chemotherapy. This research will provide evidence for optimizing antiemetic strategies in patients undergoing concurrent chemoradiotherapy.

Start Date30 Apr 2026

Sponsor / Collaborator

Henan Cancer Hospital

NCT07455955

/ RecruitingPhase 2IIT

Randomized Phase II Study of Personalized Antiemetic Regimen Based on Pharmacogenetic Profile for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients.

The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC (Fluorouracil + Epirubicin + Cyclophosphamide) chemotherapy. It also aims to compare the quality of life of patients in the first cycle of AC / FEC chemotherapy with and without PG analysis.
Patients will be randomized to undergo PG analysis [PG group] versus no PG analysis [Non-/+PG group]. Those in the PG group would be offered currently available optimal antiemetic prophylaxis, with or without Olanzapine according to PG outcomes. Those in the Non-PG group would be offered currently available optimal antiemetic prophylaxis.

Start Date31 Mar 2026

Sponsor / Collaborator

The Chinese University of Hong Kong

NCT07482891

/ Not yet recruitingPhase 4IIT

An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy

This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by hyperemetic chemotherapy (HEC) over multiple days. Eligible subjects were screened and assigned to Arm 1 or Arm 2 according to medical protocol. Arm 1: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone + Olanzapine; Arm 2: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone. Study drug administration commenced within 48 hours post-randomization, with follow-up visits and examinations completed as per protocol.

Start Date10 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Olanzapine

100 Translational Medicine associated with Olanzapine

100 Patents (Medical) associated with Olanzapine

11,782

Literatures (Medical) associated with Olanzapine

01 Jul 2026·JOURNAL OF AFFECTIVE DISORDERS

Sequenced treatment alternatives to relieve adolescent depression: A pragmatic clinical trial

Article

Author: Wen, Yulin ; Cheng, Hongyi ; Zhou, Xinyu ; Li, Xuemei ; Liu, Xueer ; Jiang, Xiaocong ; Xian, Yu ; Xu, Xiaoxia ; Qin, Bingjie ; Teng, Teng ; He, Yuqian ; Qiu, Tian ; Li, Yao ; Wang, Ting

BACKGROUND:

Adolescent major depressive disorder (MDD) is a widespread mental health condition for which treatment outcomes remain suboptimal. For adolescents, it remains unclear whether fluoxetine monotherapy or fluoxetine combined with cognitive-behavioral therapy (CBT) is more effective as an initial treatment. Additionally, no research has compared augmentation versus switching strategies after initial fluoxetine failure.

METHOD:

We conducted a multistep, multicenter, pragmatical clinical trial with a partially randomized design. In step 1, patients had the opportunity to choose treatment with fluoxetine monotherapy or combined fluoxetine and CBT treatment. In step 2, nonresponders were randomized to switch to sertraline, vortioxetine, or duloxetine, or to augment fluoxetine with aripiprazole, olanzapine, or lithium. The primary outcome was the response rate. Secondary outcomes included changes in depression, anxiety, global severity, sleep quality, and quality of life scores. Safety was assessed through mania, suicidality, and adverse events.

RESULTS:

No significant differences were observed between treatment strategies in terms of primary outcomes or adverse events. In exploratory analysis, olanzapine augmentation showed greater improvement in sleep quality compared to duloxetine switching, and similar result were found in post hoc comparisons. Aripiprazole augmentation aenhanced life of quality compared to duloxetine switching.

LIMITATIONS:

Limitations include a small sample size and lack of control and blinding.

CONCLUSION:

In this study, fluoxetine combined with CBT showed no significant advantage over fluoxetine monotherapy. All strategies in step 2 were feasible and acceptable. Our findings supported the feasibility of th sequential treatment pathway for adolescent MDD and provided insights for future adequately powered trials.

01 Jun 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Intramuscular droperidol, olanzapine, midazolam, or lorazepam to treat methamphetamine intoxication in the emergency department

Article

Author: Olives, Travis D ; Miner, James R ; O'Flaherty, Jamie L ; DeVries, Paige A ; Martel, Marc L ; Cole, Jon B ; Arens, Ann M ; Driver, Brian E

INTRODUCTION:

Emergency department (ED) visits for acute methamphetamine-associated agitation are increasing. Many cases require parenteral medications. Benzodiazepines are often recommended first-line, however randomized trials of intravenous medications suggest antipsychotics are also effective. High-quality data on intramuscular medications are lacking.

OBJECTIVE:

To compare the effectiveness of intramuscular droperidol, olanzapine, midazolam, and lorazepam to treat methamphetamine-associated agitation in the ED.

METHODS:

This was a secondary analysis of previously published data from 2019 to 2020; medication, dose, route, and agitation etiology were determined by treating physicians. The primary outcome was time to adequate sedation (TAS), assessed via the Altered Mental Status Scale (AMSS), defined as time to AMSS≤0. Secondary outcomes included use of additional (rescue) medications and adverse events.

RESULTS:

We analyzed 122 patients with similar baseline characteristics; 37 received droperidol (median dose 5 mg, TAS 16 min), 44 received olanzapine (median dose 10 mg, TAS 16 min), 15 received midazolam (median dose 5 mg, TAS 13 min), and 26 received lorazepam (median dose 2 mg, TAS 29 min). Proportional hazards analysis showed lorazepam was associated with longer TAS (p < 0.001). The proportion of patients adequately sedated at 15 min was 43% for droperidol, 45% for olanzapine, 60% for midazolam, and 32% for lorazepam. The proportion of patients receiving rescue medication was 16% for droperidol, 20% for olanzapine, 13% for midazolam, and 46% for lorazepam. We found no difference in adverse events.

CONCLUSIONS:

Intramuscular droperidol, olanzapine, and midazolam were all similarly effective for treating methamphetamine-associated agitation. All three medications provided more rapid and effective sedation than intramuscular lorazepam.

01 May 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Associations of common antipsychotic medications with weight gain in youth and adults: a target trial emulation study

Article

Author: Daley, Matthew F ; Block, Jason P ; Lin, Pi-I D ; Bailey, L Charles ; Jones, W Schuyler ; Rifas-Shiman, Sheryl L ; Petimar, Joshua ; Lunsford, Doug ; Yu, Han ; Janicke, David M ; Heerman, William J ; Toh, Sengwee ; Young, Jessica G ; Lewis, Kristina H

BACKGROUND:

Few real-world studies have estimated differences in weight gain between antipsychotic medications. This study estimated effects of initiating 4 first-line antipsychotic medications on weight change in adults and children/adolescents.

METHODS:

Electronic health record data were collected from 31,270 adults (≥20 years) and 29,496 children/adolescents (<20 years) newly prescribed 1 of 4 antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone) from 2010 to 2019 across 15 U.S. health systems. Target trial emulation estimated the effect of initiating each medication on weight change in adults and body mass index z-score (BMIz) in children/adolescents at 6 (primary) and 12 months (secondary) versus aripiprazole (reference). Inverse probability weighted estimation of repeated outcome marginal structural models adjusted for baseline confounding and informative outcome measurement.

RESULTS:

In adults, initiation of aripiprazole was associated with greater 6-month weight change than initiation of olanzapine (difference = -0.60 kg [95% CI: -0.97, -0.25]), quetiapine (difference = -1.17 kg [-1.43, -0.91]), and risperidone (difference = -0.35 kg [-0.73, 0.03]); 12-month weight gain was similar between aripiprazole and olanzapine (difference = -0.11 [-0.61, 0.38]). In children/adolescents, olanzapine was associated with greater 6-month BMIz change than aripiprazole (difference = 0.15 [0.10, 0.20]); quetiapine and risperidone were associated with slightly smaller BMIz increases than aripiprazole. Six-month adherence was lower for olanzapine (5-7%) than other medications (15-21%) in adults and children/adolescents.

CONCLUSIONS:

Among 4 first-line antipsychotic medications, aripiprazole was associated with the greatest 6-month weight gain in adults and olanzapine was associated with the greatest 6-month BMIz increase in children/adolescents, though adherence was lower for olanzapine than other medications. Clinicians should consider these differences in weight gain when initiating antipsychotic medications.

190

News (Medical) associated with Olanzapine

01 Apr 2026

·www.biospace.com

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia. There are currently no FDA-approved treatments with this indication. The Phase 3 trial will enroll approximately 380 patients across roughly 40 clinical sites worldwide, including the United States (US) and multiple European countries. This confirmatory Phase 3 trial follows productive discussions with the FDA on the overall design and efficacy assessments. It builds directly on Minerva’s clinical success in the prior pivotal Phase 2b and Phase 3 trials (C03 and C07), both of which demonstrated consistent improvements in negative symptoms with the 64 mg dose of roluperidone. “Initiation of this confirmatory Phase 3 trial is an important milestone for Minerva and for patients living with persistent and impairing negative symptoms of schizophrenia,” said Dr. Remy Luthringer, Executive Chairman and CEO of Minerva Neurosciences. “With no approved treatments for this indication in the US, roluperidone remains the only late-stage candidate in development for this population. The study builds directly on our prior experience showing consistent results across the two earlier trials and our execution strategy gives us confidence in our timelines.” “Patients with schizophrenia often live with persistent negative symptoms such as avolition and anhedonia - challenges that remain even when positive symptoms are controlled with current therapies,” said Dr. Elan Cohen, Principal Investigator at CenExel Marlton, New Jersey and Lead Coordinating Investigator for the trial. “By evaluating roluperidone in a population with stable positive symptoms, this trial isolates its potential to improve these core drivers of disability while laying the groundwork for a broader treatment strategy. Strengthening motivation, cognition, and functioning may ultimately support more comprehensive symptom control over time, and the consistency seen in prior studies makes this confirmatory Phase 3 trial especially compelling.” About the Phase 3 MIN-101C19 Trial The global Phase 3 MIN-101C19 trial will enroll approximately 380 adults aged 18–55 with moderate to severe negative symptoms of schizophrenia, confirmed by a Positive and Negative Syndrome Scale (PANSS) negative subscale score greater than 20 and stable positive symptoms for at least six months. The trial utilizes a two-part design. The overall objective of the study is to confirm the effect of roluperidone on primary negative symptoms at 12 weeks compared to placebo and to evaluate longer-term relapse of positive symptoms compared with commonly prescribed antipsychotic medications for an additional 40 weeks. The trial is designed to minimize variability and maximize sensitivity to treatment effect, including standardized assessments, and comprehensive caregiver engagement. Topline data from the 12-week Phase A portion (i.e., primary efficacy endpoint) of the trial are expected in the second half of 2027. The trial’s operational model includes intensive rater training, real-time monitoring of scoring data, and structured caregiver outreach to support safety tracking, functional assessments, and adherence. Phase A is a12-week, randomized, double-blind, placebo-controlled phase during which patients will receive 64 mg of roluperidone or placebo to evaluate the primary endpoint: change from baseline in the Marder Negative Symptoms Factor Score (NSFS), which is a factor-analytic composite created from selected PANSS items. The sole key secondary endpoint is the change from baseline in the Personal and Social Performance (PSP) total score. Other secondary endpoints include a broad set of additional clinical measures, including PANSS subscales, Clinical Global Impression – Severity (CGI-S), Clinical Global Impression – Improvement (CGI-I), the Calgary Depression Scale, avolition-specific analyses, and patient and caregiver treatment-satisfaction ratings. Phase B extends the trial for 40 weeks using a double-dummy, active-controlled, randomized design comparing continued roluperidone with three commonly prescribed antipsychotic medications (risperidone, aripiprazole, or olanzapine). This phase is designed to compare relapse rates between treatment groups. Relapses of positive symptoms will be evaluated using a rigorous, multi-component definition incorporating psychometric endpoints based on PANSS score worsening, and clinically meaningful events such as hospitalization or dangerous behavior. About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website . Forward-Looking Safe Harbor Statement This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the anticipated clinical benefits and market opportunities associated with roluperidone, including its potential to address clinical and regulatory challenges; and the expected timeline, design, and conduct of Minerva’s Phase 3 trial of roluperidone. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, trials and studies may be delayed and may not have satisfactory outcomes, and earlier trials and studies may not be predictive of later trials and studies; the design and rate of enrollment for clinical trials, including the current design of the confirmatory Phase 3 trial evaluating roluperidone may not enable successful completion of the trial(s); the commercial opportunity for roluperidone in negative symptoms of Schizophrenia may be smaller than anticipated; Minerva may be unable to obtain and maintain regulatory approvals; Minerva may experience uncertainties inherent in the initiation and completion of clinical trials and clinical development; Minerva’s future financial performance and position may not improve, resulting in difficulties in implementing Minerva’s business strategy, and plans and objectives for future operations; the expected sufficiency of Minerva’s existing cash resources and runway may not be accurate resulting in the need for additional financing sooner than anticipated or unexpected liquidity constraints; the internal and external costs required for Minerva’s ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Minerva’s plans or both; the need to align with collaborators or partners may hamper or delay development and regulatory efforts or increase costs; uncertainties of patent protection and litigation; general economic conditions; and other factors that are described under the caption “Risk Factors” in Minerva’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission. Copies of reports filed with the SEC are posted on Minerva’s website at The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law. Contacts: Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. info@minervaneurosciences.com Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com

Phase 3Phase 2

26 Mar 2026

·www.biospace.com

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy. The presentation titled “A Study of Roluperidone Coadministered with Olanzapine in Patients with Negative Symptoms of Schizophrenia” is being delivered by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences and highlights safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings from the trial. The trial was designed to assess potential interactions between roluperidone and a widely used antipsychotic, olanzapine. The trial shows no clinically significant adverse effects, no meaningful pharmacokinetic (PK) changes, and no pharmacodynamic (PD) changes during combined administration. Presentation Details Title: Olanzapine Added to Roluperidone, in Patients With Schizophrenia and Moderate to Severe Negative Symptoms: A Safety Open-Label Trial Presenter / Co-Author: Michael Davidson, MD Session: Pharmaceutical Pipeline Session Chair: Dr. Mark Weiser Date: Thursday, March 26, 2026 Session Time: 10:30 AM – 12:00 PM Location: Room Verde Presentation Time: 11:42 AM – 12:00 PM (CET) The presentation will be made available following the conference on Minerva’s website under the Presentations section at: . About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website . Contacts: Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. info@minervaneurosciences.com Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com

Phase 3

11 Mar 2026

·endpoints.news

After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there

Can Eli Lilly escape the boom-and-bust cycle that has long defined the pharma business? In January, Lilly CEO David Ricks was on stage with Nvidia CEO Jensen Huang. Ricks had recently (if briefly) joined the trillion-dollar club, a rarefied set of corporate chiefs whose companies have touched or exceeded that stratospheric valuation. Huang, a longtime member, wears it with the relaxation of his ever-present leather motorcycle jacket. Ricks, more often found in a sport jacket, is new to the club. To keep his spot, Ricks is trying to do what no pharma company has succeeded in. He needs to turn the windfall from Lilly’s massive success in weight loss into building a pipeline — and new technological approaches — that’s so broad, so forward-looking and so lucky, that he defies the gravitational pull of blockbuster patent expiries that reliably hauls down every high-flying drugmaker. On stage with Huang at an Nvidia event in San Francisco, Ricks called it achieving “exit velocity.” To do that, Lilly has undertaken a range of unusual ideas that could leave an impact on the biopharma ecosystem. While it’s busy building out its weight loss franchise with additional assets, it’s also partnering with Nvidia on a new AI-powered discovery lab , constructing an industry-leading supercomputer , offering an AI model-for-data swap to biotechs, leaning heavily into direct-to-patient sales , and partnering with the VC firm a16z on a new biotech fund . If it all works, Lilly could not only redefine the boundaries of drug company economics, but leave its stamp on the broader healthcare system itself. If it fails, the company — and Ricks — could end up redefining the meaning of “the bigger they are, the harder they fall.” “Lilly has a blend of exuberance and confidence of being the first trillion-dollar pharma combined with the paranoia and anxiety of sitting on what will become the biggest patent cliff in the industry’s history,”said Elliot Hershberg, who helps lead biotech investing at the VC firm Amplify Partners. He added that he views Lilly as playing on a different chessboard than the rest of the drugmaking giants. Ricks has brought an obsession with speed to Lilly, driven perhaps by his own memories of how quickly financial fortunes can turn. It has experienced two crushing patent cliffs, one with Prozac in 2001 and another with Zyprexa in 2011, that left the company as one of the industry’s least loved, until its recent success hauled it to new heights. Ricks called speed the most important element to improving R&D, therefore boosting Lilly’s future beyond today’s weight loss successes. The key patent for the main ingredient in Mounjaro and Zepbound won’t expire until 2036, but when that time comes, the loss could be enormous. “The challenge before us now is, how do we find another success cycle before that one runs out — hopefully a lot sooner than when it runs out,” Ricks told Huang, “and sort of get exit velocity. There’s really no major company in our industry that’s done that.” Ricks joined Lilly’s marketing department in 1996. He went from running the Canadian market to the Chinese market, eventually becoming CEO in 2017. In his first performance management review as the company’s leader, he was told he had an “overdeveloped sense of urgency.” That’s trickled down to the rest of the 50,000-employee company. “We have an impatient CEO,” Lilly’s chief information and digital officer Diogo Rau said in an interview, when asked about the collaboration with Nvidia. The companies are building a first-of-its-kind Bay Area laboratory that will physically co-locate scientists from both organizations to work on a range of AI moonshots in biopharma. The arrangement started with texts between Ricks and Huang last year. The goal is to open the Bay Area lab by the end of March, Rau said, a far faster speed than most big pharma companies typically build. Rau departed Apple to join Lilly in 2021. Some ex-Apple folks who followed him have told him they’re amazed by “how fast we move here,” he said. The speed means a lot of deals. Ricks said at his JPM presentation the business development team averaged a deal every nine days in 2025, totaling 39 on the year — far more than any other rival company. Many of these deals are a bit out-there compared to the standard, pipeline-stuffing tendency of large drugmakers. Some are higher-risk projects, like Verve’s cholesterol-lowering gene editing program or Ventyx’s inhibitors against NLRP3 , a target tied to aging-related diseases. Others, like the lab with Nvidia and bankrolling the a16z fund, are structured in ways even further divorced from the aim of bringing in specific drugs to boost revenue. Absent are any big, late-stage deals. Rau said the underlying driver is a willingness to “make bets on things we have high conviction on.” “We don’t necessarily require a brute financial case that might take three months to build,” Rau said. “We’ve learned from our past decisions that we regret more the things that we haven’t done or moved quickly on than the things we have done.” One of its first deals of 2026 was with Chai Discovery , an AI startup developing some leading protein design models. Its co-founders said the Lilly team was in its San Francisco office the week after it released details on its Chai-2 model last summer. Just a few months later, they became Chai’s first announced pharma partner. “They’ve just run through all sorts of walls to get the approvals they needed to make this happen really quickly,” Chai co-founder Jack Dent said in an interview. “That’s going to pay massive dividends for them. Other companies may want to take note.” Pharma peers, by comparison, seem like they’re treading water. Sanofi has struggled to answer what comes next after Dupixent, recently ousting Paul Hudson as CEO. Merck and Pfizer have made a flurry of expensive deals and major restructurings to brace for their own upcoming patent expiries on key drugs like Keytruda and Eliquis, which are expected before the end of this decade. Lilly has the chance to pursue a different fate. That will likely require hitting on some of the big-swinging ideas that could unlock huge patient populations, if successful. Those include a cholesterol-lowering gene editing program, large Alzheimer’s prevention studies, and non-opioid pain medications in the pipeline. “They’re incredibly ambitious, long-term thinkers,” a16z general partner Vineeta Agarwala said in an interview. “I do not think they are chasing patent cliffs.” It also hasn’t led to empire building, or a loss of discipline. Ricks says he has tried to keep headcount flat, and Lilly’s headcount grew by about 3,000 people, or 6%, over the last year, even as its revenue grew by 45% last year. He weighs in on all new hires and promotions above a certain level. “That makes me very unpopular,” he said on a recent podcast, an unusual, free-flowing two-hour-long conversation that sounded more like the loose, tech-cool Huang than the typical pharma CEO. “People are like, ‘How do I get this work done?’” The comparison extends to its market valuation, which makes Lilly look more like a Silicon Valley tech darling than a drugmaker. Lilly has kept a frenetic pace since the JP Morgan conference, when Ricks was on stage with Huang. They have given hints of what could be the next piece of the obesity story, in combination trials with some of its other drugs like Taltz that appear to boost efficacy in conditions like psoriasis. Outside of obesity, the first weeks of the year have included partnerships on gene editing and immunology, an acquisition of an in vivo CAR-T therapy, a sweeping R&D deal with a Chinese biotech powerhouse, and the announcement of a new Allentown, PA factory alongside Gov. Josh Shapiro. The unavoidable fate of pharma looms around every corner: Look no further than the downfall of its chief GLP-1 rival Novo Nordisk. In May, Lilly will celebrate its 150th anniversary. Next year, Ricks will celebrate his 10-year anniversary in the CEO job. For now, he and the company are on top. The real question is how long they can stay there.

AcquisitionExecutive Change

100 Deals associated with Olanzapine

External Link

KEGG	Wiki	ATC	Drug Bank
D00454	Olanzapine	N05AH03	DB00334

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	Japan	CHEPLAPHARM Arzneimittel GmbH	25 Dec 2017
Chemotherapy-induced nausea and vomiting	Japan	Eli Lilly & Co.	25 Dec 2017
Agitation	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Depressive Disorder	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Depressive Disorder, Treatment-Resistant	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Bipolar and Related Disorders	China	Eli Lilly & Co.	01 Jan 2006
Bipolar I disorder	United States	CHEPLAPHARM Arzneimittel GmbH	30 Sep 1996
Bipolar Disorder	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 3	China	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	01 Oct 2020
Vomiting	Phase 3	China	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	01 Oct 2020
Gambling	Phase 3	United States	Eli Lilly & Co.	01 Feb 2007
Weight Gain	Phase 3	United States	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Brazil	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Israel	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Mexico	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Russia	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	South Korea	Eli Lilly & Co.	01 Nov 2006
Borderline Personality Disorder	Phase 3	United States	Eli Lilly & Co.	01 Feb 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05803642 (Pubmed \| Drug Des Devel Ther)	Phase 3	Agitation	317	QLG2072 (10 mg per injection)	odgdhzfsdx(aqjbitight) = lkxvpgoqez fevxensfet (qiyvtbhbva, -10.02 to -8.72) View more	Non-inferior	01 Feb 2026
				Haloperidol (7.5 mg per injection)	odgdhzfsdx(aqjbitight) = uzowqbieco fevxensfet (qiyvtbhbva, -10.04 to -8.75) View more
NCT06319170 (CTgov)	Phase 1	Schizoaffective disorder \| Schizophrenia	106	Olanzapine (Cohort 1: Olanzapine (Fast-D))	xropbohudd(oyrfwqelfi) = bjfmpbkunb ijdbepkupw (yeepqqpshn, 45.10) View more	-	26 Jan 2026
				Olanzapine (Cohort 2: Olanzapine (To-be-marketed))	xropbohudd(oyrfwqelfi) = pwcatyorxh ijdbepkupw (yeepqqpshn, 67.55) View more
ESMO_ASIA2025	Not Applicable	Chemotherapy-induced nausea and vomiting	139	Olanzapine+ondansetron+dexamethasone	aoombgtznz(zqgfagsmtv) = exbczigjcc kzygppgwty (ietebvwzqe ) View more	Positive	06 Dec 2025
				Placebo+ondansetron+dexamethasone	aoombgtznz(zqgfagsmtv) = exiqtotwme kzygppgwty (ietebvwzqe ) View more
ESMO_ASIA2025	Not Applicable	Lung Cancer	154	Low dose olanzapine	urfokkzfaa(fkdmzsepsn) = wdodzinxbx jkuiajykam (exssyvwkoa ) View more	Positive	06 Dec 2025
				Megestrol acetate	urfokkzfaa(fkdmzsepsn) = wysciqfmpq jkuiajykam (exssyvwkoa ) View more
ESMO_ASIA2025	Not Applicable	Chemotherapy-induced nausea and vomiting	113	NK-1 RA	beykdheugh(zecncqbboi) = zlipbowjkb qgzjogpahw (ozftzijtfg ) View more	Positive	06 Dec 2025
				Olanzapine	beykdheugh(zecncqbboi) = btyfdsppnh qgzjogpahw (ozftzijtfg ) View more
NCT04076371 (Pubmed \| Curr Neuropharmacol)	Phase 2	Schizophrenia	196	Low-dose olanzapine/sertraline	fnyozwqeqo(hhuvqnvolv) = psdfsuduei iyhjftcpfw (xxaupnlkir ) View more	Positive	03 Nov 2025
				Standard-dose olanzapine	fnyozwqeqo(hhuvqnvolv) = xjublisota iyhjftcpfw (xxaupnlkir ) View more
NCT03367572 (CTgov)	Phase 3	Nausea \| Breast Cancer \| Vomiting	1,363	Quality-of-Life Assessment+Dexamethasone+Netupitant/Palonosetron Hydrochloride (Group I (Netupitant/Palonosetron Hydrochloride, Dexamethasone)	wxnflxnxco(vefestjarg) = cvnnvvzcuy icsxxpgtse (dyeaqordqr, 0.155) View more	-	25 Sep 2025
				Quality-of-Life Assessment+Prochlorperazine+Dexamethasone+Netupitant/Palonosetron Hydrochloride (Group II (Net/Pal Hydro, Dexa, Prochlorperazine, Placebo))	wxnflxnxco(vefestjarg) = tnfbtoavvu icsxxpgtse (dyeaqordqr, 0.141) View more
NCT05693935 (SOLARIS, GlobeNewswire) Manual	Phase 3	Schizophrenia	675	Olanzapine LAI (all doses pooled)olanzapine (P2: including olanzapine → olanzapine and placebo → olanzapine groups)	piaiscavku(uzmanbuqhj) = oppapcrevc wldztrfjdo (qjhxmdhoug ) View more	Positive	20 Sep 2025
JPRN-jRCT1031200134 (Pubmed \| Lancet Oncol) Manual	Phase 3	Breast Cancer	480	olanzapine 5mg	zlobymjxlh(vmddqpawrc) = rsnipztcdp vcolcguzbt (zqqutfxiwc ) View more	Positive	18 Jun 2025
				placebo	zlobymjxlh(vmddqpawrc) = alavcpxzyv vcolcguzbt (zqqutfxiwc ) View more
NCT04503668 (CTgov)	Phase 3	Female Genital Neoplasms \| Nausea \| Vomiting	62	Compazine+Dexamethasone+Ondansetron+Neurokinin-1 Receptor Antagonist (NK1-RA) (Nk1-RA)	rzvdnquspd = zudkmzljjn vawlbdicgq (enlsijhdao, iupvusjtkt - ygnxprlkns) View more	-	18 Jun 2025
				Compazine+Olanzapine+Dexamethasone+Ondansetron (Olanzapine)	rzvdnquspd = dizkiqnqfp vawlbdicgq (enlsijhdao, wtpcjhelmn - dmxavhikxx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Olanzapine

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation